Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207707 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
A Phase 1 study of Solid Tumor Malignancies, sponsored by Kumquat Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 12
- Study locations
NCT07207707: Recruiting Phase 1 study of Solid Tumor Malignancies, sponsored by Kumquat Biosciences.
NCT07207707 is a Phase 1 study of Solid Tumor Malignancies that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 78 participants, below the 189-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (59% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07207707, a Phase 1 study of Solid Tumor Malignancies, is actively recruiting participants, sponsored by Kumquat Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?
Primary Outcome
Safety characterized by type, incidence and severity of treatment emergent adverse events (TEAEs), SAEs, and DLTs
Conditions Studied
Interventions
- DRUG KQB548
Study Locations (12)
Texas
- NEXT Oncology - Austin - Austin
- MD Anderson Cancer Center - Houston
- NEXT Oncology - Dallas - Irving
- NEXT Oncology - San Antonio - San Antonio
California
- University of California, San Diego - La Jolla
- University of California, Los Angeles - Los Angeles
Colorado
- SCRI - Denver - Denver
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Michigan
- START Midwest - Grand Rapids
Ohio
- The Christ Hospital - Cincinnati
Utah
- University of Utah - Huntsman Cancer Institute - Salt Lake City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT07207707 shows while recruiting
NCT07207707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 189-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 1 intervention - of which KQB548 is the first listed.
NCT07207707 lists 12 locations in 8 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT07207707 about?
NCT07207707 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies". The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? ...
What is the current status of trial NCT07207707?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2025-09-16. Estimated completion is 2027-03.
What conditions does trial NCT07207707 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies.
What interventions are being tested in trial NCT07207707?
The interventions under investigation include: KQB548 (DRUG).
Who is sponsoring clinical trial NCT07207707?
This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207707 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07207707's enrollment target sits among peer trials
78 10th of 11 higher than 2 of 11 other Solid Tumor Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI